Mihály Z and Gyõrffy B |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. |
2013 |
Magy Onkol |
pmid:24107820
|
Dank M and Tõkés T |
[Monoclonal antibody therapy in breast cancer]. |
2013 |
Magy Onkol |
pmid:24107821
|
Yaqub F |
T-DM1 for HER2-positive metastatic breast cancer. |
2013 |
Lancet Oncol. |
pmid:23580966
|
Hurvitz SA et al. |
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2013 |
J. Clin. Oncol. |
pmid:23382472
|
Yue W et al. |
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. |
2013 |
J. Exp. Ther. Oncol. |
pmid:24416991
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24662957
|
Haddley K |
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. |
2013 |
Drugs Today |
pmid:24308017
|
|
T-DM1 aids patients with advanced breast cancer. |
2013 |
Cancer Discov |
pmid:24327714
|
Haddish-Berhane N et al. |
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. |
2013 |
J Pharmacokinet Pharmacodyn |
pmid:23933716
|
Barroso-Sousa R et al. |
Biological therapies in breast cancer: common toxicities and management strategies. |
2013 |
Breast |
pmid:24144949
|
Ismaili N et al. |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. |
2013 |
Presse Med |
pmid:23721860
|
Wood AC et al. |
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. |
2013 |
Pediatr Blood Cancer |
pmid:23798344
|
Drachman JG and Senter PD |
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. |
2013 |
Hematology Am Soc Hematol Educ Program |
pmid:24319196
|
Dirix LY et al. |
Trastuzumab emtansine in breast cancer. |
2013 |
Expert Opin Biol Ther |
pmid:23477731
|
Wings S et al. |
A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. |
2013 |
Phytochemistry |
pmid:22795602
|
Carol H et al. |
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. |
2013 |
Clin. Cancer Res. |
pmid:23426279
|
Peddi PF and Hurvitz SA |
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. |
2013 |
Future Oncol |
pmid:23469968
|
Chu YW and Polson A |
Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. |
2013 |
Future Oncol |
pmid:23469971
|
Dagger F et al. |
Regulatory volume decrease in Leishmania mexicana: effect of anti-microtubule drugs. |
2013 |
Mem. Inst. Oswaldo Cruz |
pmid:23440120
|
Boyraz B et al. |
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. |
2013 |
Curr Med Res Opin |
pmid:23402224
|
Pan W et al. |
Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. |
2013 |
Sci China Life Sci |
pmid:23832249
|
Bighin C et al. |
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. |
2013 |
Future Oncol |
pmid:23837759
|
Johnson MS |
The top 10 drug trends right now. |
2013 |
Nurs Manage |
pmid:23764906
|
Gradishar WJ |
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. |
2013 |
Ann. Oncol. |
pmid:23827380
|
Dere R et al. |
PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. |
2013 |
Bioanalysis |
pmid:23641694
|
Pode-Shakked N et al. |
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. |
2013 |
EMBO Mol Med |
pmid:23239665
|
Konecny GE |
Emerging strategies for the dual inhibition of HER2-positive breast cancer. |
2013 |
Curr. Opin. Obstet. Gynecol. |
pmid:23241641
|
Cho WC and Roukos DH |
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. |
2013 |
Expert Rev Anticancer Ther |
pmid:23259420
|
Noguchi E and Shimizu C |
[T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. |
2013 |
Gan To Kagaku Ryoho |
pmid:23306913
|
Faião-Flores F et al. |
Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. |
2013 |
Tumour Biol. |
pmid:23341182
|
Siyu-Mao et al. |
Two novel ansamitocin analogs from Actinosynnema pretiosum. |
2013 |
Nat. Prod. Res. |
pmid:23061718
|
Zolot RS et al. |
Antibody-drug conjugates. |
2013 |
Nat Rev Drug Discov |
pmid:23535930
|
Traynor K |
Ado-trastuzumab emtansine approved for advanced breast cancer. |
2013 |
Am J Health Syst Pharm |
pmid:23515502
|
Lu D et al. |
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. |
2013 |
Clin Pharmacokinet |
pmid:23553425
|
DeFrancesco L |
Drug pipeline: 1Q13. |
2013 |
Nat. Biotechnol. |
pmid:23752422
|
Pegram M |
Treatment combinations for HER2-positive breast cancer. |
2013 |
Oncology (Williston Park, N.Y.) |
pmid:23781688
|
Yamashita-Kashima Y et al. |
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. |
2013 |
Oncol. Rep. |
pmid:23783223
|
Deckert J et al. |
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. |
2013 |
Blood |
pmid:24002446
|
Sapra P et al. |
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. |
2013 |
Expert Rev Clin Pharmacol |
pmid:23978126
|
Mancuso L et al. |
Bioreduction of aryl azides during mutasynthesis of new ansamitocins. |
2013 |
Org. Lett. |
pmid:23981134
|
Palomba ML and Younes A |
In the spotlight: a novel CD37 antibody-drug conjugate. |
2013 |
Blood |
pmid:24235129
|
Poon KA et al. |
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. |
2013 |
Toxicol. Appl. Pharmacol. |
pmid:24035823
|
Beck A et al. |
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. |
2012 Nov-Dec |
MAbs |
pmid:22909934
|
Chudasama VL et al. |
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. |
2012 |
Clin. Pharmacol. Ther. |
pmid:22968044
|
Gonçalves A et al. |
[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. |
2012 |
Bull Cancer |
pmid:23247898
|
Janthur WD et al. |
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. |
2012 |
Int J Mol Sci |
pmid:23443108
|
Dixon JM et al. |
HER2 testing in patients with breast cancer. |
2012 |
BMJ |
pmid:22689887
|
Olson EM et al. |
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. |
2012 |
Ann. Oncol. |
pmid:21531783
|
Lapusan S et al. |
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. |
2012 |
Invest New Drugs |
pmid:21519855
|
Gurtner K et al. |
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. |
2012 |
Radiother Oncol |
pmid:22100655
|
Eichner S et al. |
The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. |
2012 |
Angew. Chem. Int. Ed. Engl. |
pmid:22135226
|
Gupta M et al. |
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. |
2012 |
J Clin Pharmacol |
pmid:21953571
|
Shen BQ et al. |
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. |
2012 |
Nat. Biotechnol. |
pmid:22267010
|
Girish S et al. |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22271209
|
Garzone PD and Atkinson AJ |
In search of physiologically based distribution volume estimates for macromolecules. |
2012 |
Clin. Pharmacol. Ther. |
pmid:22992670
|
Matsubara Y |
A Meg by any other name. |
2012 |
Blood |
pmid:22956528
|
Taft F et al. |
Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. |
2012 |
Chemistry |
pmid:22170289
|
Kang Q et al. |
Biosynthesis of 3,5-AHBA-derived natural products. |
2012 |
Nat Prod Rep |
pmid:22193711
|
Davis JA et al. |
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. |
2012 |
Drug Metab. Dispos. |
pmid:22752008
|
Younes A et al. |
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. |
2012 |
J. Clin. Oncol. |
pmid:22753910
|
Lu D et al. |
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. |
2012 |
Curr. Drug Metab. |
pmid:22475266
|
Shen BQ et al. |
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. |
2012 |
Curr. Drug Metab. |
pmid:22475269
|
Ito Y |
[Progress of molecularly targeted therapy for breast cancer]. |
2012 |
Rinsho Ketsueki |
pmid:22687976
|
Beeram M et al. |
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. |
2012 |
Cancer |
pmid:22648179
|
Krop IE et al. |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. |
2012 |
J. Clin. Oncol. |
pmid:22649126
|
Thon JN et al. |
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. |
2012 |
Blood |
pmid:22665936
|
Segraves NL et al. |
An isolable acyclic hemiacetal of ansamitocin P-3. |
2012 |
Magn Reson Chem |
pmid:22374862
|
Erickson HK et al. |
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. |
2012 |
Mol. Cancer Ther. |
pmid:22408268
|
Bender BC et al. |
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22886072
|
Erickson HK and Lambert JM |
ADME of antibody-maytansinoid conjugates. |
2012 |
AAPS J |
pmid:22875610
|
Damodaran S and Olson EM |
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. |
2012 |
Hosp Pract (1995) |
pmid:23299030
|
|
Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. |
2012 |
Harv Health Lett |
pmid:23243689
|
Barginear MF et al. |
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. |
2012 |
Mol. Med. |
pmid:23196784
|
Teicher BA and Doroshow JH |
The promise of antibody-drug conjugates. |
2012 |
N. Engl. J. Med. |
pmid:23134386
|
Verma S et al. |
Trastuzumab emtansine for HER2-positive advanced breast cancer. |
2012 |
N. Engl. J. Med. |
pmid:23020162
|
|
Interest in "smart bombs" explodes. |
2012 |
Cancer Discov |
pmid:23071018
|
Bander NH et al. |
Antibody-drug conjugate technology development for hematologic disorders. |
2012 |
Clin Adv Hematol Oncol |
pmid:23072775
|
Beck A et al. |
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. |
2011 Jul-Aug |
MAbs |
pmid:21691144
|
Lin J et al. |
Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum. |
2011 |
Bioresour. Technol. |
pmid:20980145
|
Jia Y and Zhong JJ |
Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. |
2011 |
Bioresour. Technol. |
pmid:21907573
|
Junttila TT et al. |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. |
2011 |
Breast Cancer Res. Treat. |
pmid:20730488
|
Wu Y et al. |
N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. |
2011 |
Chembiochem |
pmid:21681880
|
Sun X et al. |
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. |
2011 |
Bioconjug. Chem. |
pmid:21391620
|
Kellogg BA et al. |
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. |
2011 |
Bioconjug. Chem. |
pmid:21425776
|
Lopus M |
Antibody-DM1 conjugates as cancer therapeutics. |
2011 |
Cancer Lett. |
pmid:21481526
|
Edwards A et al. |
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. |
2011 |
Dis Model Mech |
pmid:21504911
|
Barok M et al. |
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. |
2011 |
Breast Cancer Res. |
pmid:21510863
|
Zhao RY et al. |
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. |
2011 |
J. Med. Chem. |
pmid:21517041
|
Higa GM |
The microtubule as a breast cancer target. |
2011 |
Breast Cancer |
pmid:20862571
|
Allison M |
Can cancer clinical trials be fixed? |
2011 |
Nat. Biotechnol. |
pmid:21221090
|
Yang H et al. |
Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. |
2011 |
Cytoskeleton (Hoboken) |
pmid:21309084
|
Fishkin N et al. |
A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. |
2011 |
Chem. Commun. (Camb.) |
pmid:21874179
|
Hinow P et al. |
Modeling the effects of drug binding on the dynamic instability of microtubules. |
2011 |
Phys Biol |
pmid:21836336
|
LoRusso PM et al. |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
2011 |
Clin. Cancer Res. |
pmid:22003071
|
Blanc V et al. |
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. |
2011 |
Clin. Cancer Res. |
pmid:22003072
|
Mathew J and Perez EA |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. |
2011 |
Curr Opin Oncol |
pmid:21986845
|
Li Y et al. |
Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. |
2011 |
Chem. Biol. |
pmid:22195559
|
Knobloch T et al. |
Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. |
2011 |
Chembiochem |
pmid:22238146
|
Tuma RS |
Enthusiasm for antibody-drug conjugates. |
2011 |
J. Natl. Cancer Inst. |
pmid:21972230
|
Bertholjotti I |
[Antibody-drug conjugate--a new age for personalized cancer treatment]. |
2011 |
Chimia (Aarau) |
pmid:22026193
|